EntinostatSTAR0602mSTAR1302solid malignancieshuman cancersCT26EMT6
…-2R targeting to be significantly augmented by combination with Entinostat. These effects are associated with TCRVβ13/IL-2R targeting augm…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 481–540 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
SGLT2 inhibitors7Tebentafusp7ethambutol7Albumin7mSTAR13027Bimekizumab7LA7RPV7Alirocumab7Ixekizumab7TXA7pyrazinamide7Antidepressant7B7-H37Botox7Ibrutinib7Apalutamide7Heroin7MRA7Palbociclib7TGF-β17bDMARD7Enfortumab vedotin7fluoroquinolones7sintilimab7DES7IL-107Neostigmine7bDMARDs7methamphetamine7posaconazole7MDMA7Tetracycline7Labetalol7Piperacillin-tazobactam7Acyclovir7DOACs7IL-67Monoclonal antibodies7NSAID7TGF-β7DORAvirine7Nimodipine7bronchodilator7leflunomide7melphalan7metoprolol70.2% ropivacaine7Antihypertensives7NSAIDs7angiotensin receptor blockers7anticentromere7bortezomib7clindamycin7codeine7dipeptidyl peptidase-4 inhibitors7esomeprazole7flucloxacillin7Glucagon-like peptide-1 (GLP-1) receptor agonists7Janus kinase inhibitors7
Articles mentioning drugs
10,506 articles · page 174 of 876BSCgalcisplatinPD-1 inhibitorsmalignant cancersHNCcanine head and neck cancerimmunotherapySABR
…nine head and neck cancer (HNC).Results In mouse models of HNC, BSCgal enhances both radiodynamic and immune responses of SABR. It inc…
ICigranzyme Btargeted inhibitorsmelanomacutaneous melanomaC57BL/6 mice
…ssociated with differential response to targeted inhibitors and ICi. The mesenchymal-like cell state elicits an invasive phenotype …
pembrolizumabpembrolizumab-basedPD-1 inhibitorCCR8 antagonistGastric cancerFudan UniversityGCZhongshan Hospital
…nical outcomes but superior immunotherapeutic responsiveness to pembrolizumab in GC. Transcriptomic and phenotypic analyses revealed that tum…
99.4%
urelumabRBT1014-1BB MultabodyMC38
…neic MC38 tumor model where a 4-1BB Multabody was compared with urelumab. For safety assessment, we performed histopathologic analysis o…
caIL-12IL-12checkpoint inhibitorsInvasive bladder cancerNational Cancer InstituteNC State Universityinvasive urothelial carcinomaAbstractinvasive urothelial carcinomaimmunotherapyU01CA272258
… responses to intravesical CS/IL-12.Conclusions Intravesical CS/caIL-12 treatments have been generally well-tolerated. Five dose levels…
ChloroauratePembrolizumabAurothiomalateAMPancreatic cancerPDAC
…fects of gold salt on surface immune marker. Aurothiomalate and Chloroaurate upregulate ICOSL, PDL-1 and MHC-1 expression on pancreatic canc…
encorafenibdabrafenibBRAF inhibitorsPLX8934anti-PD1pancreatic adenocarcinomaNRAS mutant melanomaNRAS-mutant melanomaPDACimmunotherapy+2 more
…esponses including autophagy (figure 2C). Finally, single agent encorafenib was administered in the 3rd and 4th line in two patients with l…
RNDO-564solid tumorshematologic malignanciesmetastatic urothelial carcinomamUC
…e safety profile with no systemic T-cell activation.Conclusions RNDO-564 elicits robust Nectin-4-dependent in vitro and in vivo anti-tum…
labetuzumabP601tusamitamablungcolorectalcell-based therapiesNat Cancer 2021
…dvantages over reference CEA antibodies such as tusamitamab and labetuzumab.Results Our novel CEA mAb, P601 binds with high affinity and se…
BDC-4182BDC-4182.Sgastric cancerNCT06921837
…y, we provide supporting preclinical data supporting the use of BDC-4182 in combination with CPI in gastric cancer patients.Conclusions …
CX-908solid tumorsInovtivbreastcytokine release syndrome
…rm and shows significantly reduced cytokine release.Conclusions CX-908 shows strong anti-tumor efficacy and an improved tolerability p…